the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
NCT ID: NCT05975164
Last Updated: 2023-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2023-07-25
2024-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
NCT05491044
Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
NCT05920668
The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
NCT06489184
Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL
NCT05918276
Evaluating Different Doses of Orelabrutinib in MCL
NCT05978739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with a definite diagnosis of CLL/SLL
3. Prior or current use of orelabrutinib for ≥3 months
4. At least one follow-up was recorded during orelabrutinib treatment
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chunyan Ji
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chunyan Ji, Dr.
Role: PRINCIPAL_INVESTIGATOR
Qilu Hospital of Shandong University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Orelabrutinib in real world
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.